Using primary and recurrent BRCA1/2-mutated carcinomas from ovarian cancer patients, patient-derived lines, and an in vivo BRCA2-mutated mouse model, Meghani et al. identified that a microRNA, miR-493-5p, induced platinum/PARPi resistance exclusively in BRCA2-mutated carcinomas, and they concluded that the cumulative impact of miR-493-5p on multiple pathways related to genome stability causes PARPi/platinum resistance in BRCA2-mutated carcinomas [95]. This evidence concerns the gene BRCA2 and ovarian cancer.